New Software from Malvern Instruments Simplifies Advanced Protein Analysis by SEC
Malvern experts will be presenting at The International Symposium on Gel Permeation Chromatography (GPC)/Size Exclusion Chromatography (SEC) and Related Techniques, an event which coincides with the release of a new and improved version of their OmniSEC software for advanced protein analysis. The symposium runs 29 September to 2 October in Frankfurt, Germany. The new software, OmniSEC 5.1, makes it easy to integrate any of the Viscotek SEC detectors with Waters Empower-driven SEC systems, for powerful, efficient protein characterisation.
GPC/SEC involves separation of a sample on the basis of molecular size, followed by analysis of the resulting fractions with one or more detectors. Dr Bassem Sabagh’s presentation will demonstrate the value of triple detection SEC for hyaluronic acid (HA) characterisation. Entitled ‘Investigating the relationship between the rheological properties of HA and its molecular weight and structure using multi-detector SEC and SEC-MALS’, it will include experimental data showing the accuracy of the Viscotek SEC-MALS 20 detector for different HA samples. The resulting data are correlated with rheological measurements to quantify the impact of molecular weight distribution on viscosity.
Dr Bert Postma will focus on the technology that can be used successfully to analyse low molecular weight samples in his presentation ‘Addressing the challenge of analysing low molecular weight samples by multi-detector GPC’. The accurate measurement of low molecular weight material is a commonly encountered issue in GPC analysis.
Malvern’s new OmniSEC 5.1 can directly interrogate analytical sequences within the Waters Empower software. By eliminating the need to input sequences in duplicate, it makes an integrated system easier to use, quicker to set-up and less prone to errors.
OmniSEC 5.1 BIO is a protein-specific version of the software with calculation methods and terminology directly tailored to the specific needs of protein scientists. Combined with the Viscotek SEC-MALS 20 and new silica SEC columns with low shedding for protein light scattering applications, the new software makes it easier for protein scientists to access all the information required, whatever SEC system is being used.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.